Accessibility Menu
Bio-Techne logo

Bio-Techne(NASDAQ) TECH

Market Cap$11.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)+13,470%
5 Year-42%
1 Year+38%
1 Month+1%
Premium Feature
Moneyball Superscore
62/100
$72.42
-0.04%
-0.03Today
After hours$72.43+$0.01 (+0.01%)
Bio-Techne last closing stock price
MetricPriceDate
Last closeUSD 72.432026-09-04
Bio-Techne stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.11%USD 72.352026-08-28
1 month+0.71%USD 71.922026-08-05
3 month+39.47%USD 51.932026-06-05
Year to date+23.69%USD 58.562025-12-31
1 year+37.64%USD 52.622025-09-04
3 year-4.77%USD 76.062023-09-05
5 year-42.23%USD 125.382021-09-03
Since inception+13,469.5%USD 0.531992-06-15

Bio-Techne Financials at a Glance

Market Cap

$11.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.22B

Net Income (TTM)

$181.86M

EPS (TTM)

$1.16

P/E Ratio

62.53

Dividend

$0.32

Beta (Volatility)

1.14 (Average)

Price

$72.42

Volume

1,856,314.429

Open

$72.40

Previous Close

$72.43

Daily Range

$72.40 - $72.48

52-Week Range

$43.20 - $72.62

Estimated Earnings Date

Nov 4, 2026

TECH News

BullBearImage-Red.png

Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer

Josh Kohn-LindquistJun 25, 2026
SellAlert-Green.png

Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?

Andy GouldMar 13, 2026
Foolcom-Featured.png

Bio-Techne (TECH) Q4 EPS Rises 8.2%

Motley Fool Markets TeamAug 6, 2025
man with cup listening to wall GettyImages-511535378

Better Know Biotech: 2 Stocks You Ought to Know About

Todd CampbellMay 16, 2018

Techne Keeps Dividend Steady

Rich DupreyAug 6, 2013

Techne's Upcoming Earnings: What You Need To Know

Seth JaysonJul 29, 2013

Will Techne Whiff on Revenues Next Quarter?

Seth JaysonJun 19, 2013

Techne to Acquire Diagnostics Firm for $104 Million

Rich DupreyJun 18, 2013
Page 1

TECH: Motley Fool Moneyball Superscore

62

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bio-Techne

Bio-Techne Corp. makes tools for lab researchers and doctors. These tools help find diseases and create new drugs. They serve scientists in hospitals and universities.

Science Tools for Better Medicine

  • Protein Sciences: Specialized testing chemicals and protein analysis tools; represented 72% of net sales in fiscal 2026.
  • Diagnostics and Spatial Biology: Tests and tools for disease analysis; represented 28% of net sales in fiscal 2026.
  • Analytical Solutions: Automated instruments that measure protein levels in biological fluids for researchers.
  • Spatial Biology: Advanced imaging tools used to see genetic material within intact cells.

Strategic Moves and New Partnerships

  • Acquired Lunaphore Technologies SA in fiscal 2024 to add automated spatial biology solutions.
  • Completed a 19.9% investment in Wilson Wolf Corp. during fiscal 2023.
  • Entered a merger agreement to be acquired by Merck KGaA in June 2026.
  • Invested $15 million into Spear Bio during fiscal 2025.

Where Science Meets Quality

Bio-Techne manufactures most of its products in-house at locations across North America, Europe, and China. The company focuses on research and development to introduce new products that meet changing market needs.

The Numbers Behind the Lab

  • Consolidated net sales reached $1.2 billion in fiscal 2026.
  • Consolidated net earnings increased 148% in fiscal 2026 compared to fiscal 2025.
  • Cash and cash equivalents were $264.7 million at June 30, 2026.
  • Organic revenue remained flat in fiscal 2026 compared to the prior year.

A Look at the Future

Bio-Techne has grown into a global provider of specialized life science reagents and diagnostic tools. Its focus on automated spatial biology and the pending merger reflects its shifting role in the healthcare market.

AI Generated • Aug 25, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

3,000

CEO

Kim Kelderman

Website

www.bio-techne.com

Headquarters

Minneapolis, MN 55413, US

TECH Financials

Key Financial Metrics (TTM)

Gross Margin

65.77%

Operating Margin

20.73%

Net Income Margin

14.97%

Return on Equity

8.90%

Return on Capital

10.51%

Return on Assets

7.03%

Earnings Yield

1.60%

Dividend Yield

0.44%

Payout Ratio

27.45%

Stock Overview

Market Cap

$11.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

156.82M

Volume

1.86M

Avg. Volume

4.69M

Financials (TTM)

Gross Profit

$799.07M

Operating Income

$251.89M

EBITDA

$343.44M

Operating Cash Flow

$292.07M

Capital Expenditure

-$28.85M

Free Cash Flow

$263.22M

Cash & ST Invst.

$264.71M

Total Debt

$289.09M

Bio-Techne Performance Analysis

Bio-Techne annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 1,136,702,0002.8%
20242024-06-30USD 1,159,060,0002.0%
20252025-06-30USD 1,219,635,0005.2%
20262026-06-30USD 1,215,039,000-0.4%
Bio-Techne sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30-9.6%
Q22025-12-313.3%
Q32026-03-315.3%
Q42026-06-303.1%
Bio-Techne annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD 1.766.3%
20242024-06-30USD 1.05-40.7%
20252025-06-30USD 0.46-56.1%
20262026-06-30USD 1.16152.2%
Bio-Techne sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30318.2%
Q22025-12-31N/A
Q32026-03-3133.3%
Q42026-06-3012.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$321.19M

+1.3%

Gross Profit

$211.39M

+6.3%

Gross Margin

65.82%

N/A

Market Cap

$11.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.79M

N/A

Employees

3,000

N/A

Net Income

$54.61M

+408.9%

EBITDA

$91.90M

+1329.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$264.71M

+63.2%

Total Debt

$289.09M

-34.9%

Accounts Receivable

$216.59M

+4.7%

Inventory

$195.74M

+3.3%

Long Term Debt

$274.15M

-36.2%

Short Term Debt

$14.94M

+5.9%

Return on Assets

7.03%

N/A

Return on Invested Capital

10.40%

N/A

Free Cash Flow

$86.94M

-6.8%

Operating Cash Flow

$95.42M

-2.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CORTCorcept Therapeutics Incorporated
$111.62-1.05%
MDGLMadrigal Pharmaceuticals, Inc.
$541.08-0.28%
BMRNBioMarin Pharmaceutical Inc.
$66.53+0.15%
QGENQiagen N.V.
$43.47-0.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About TECH

What is the current price of Bio-Techne?

Bio-Techne is trading at $72.43 per share.

What is the 52-week range for Bio-Techne?

Over the past 52 weeks, Bio-Techne has traded between $43.20 and $72.62.

How much debt does Bio-Techne have?

As of the most recent reporting period, Bio-Techne reported total debt of $289.09M.

How much cash does Bio-Techne have on hand?

Bio-Techne reported $264.71M in cash and cash equivalents in its most recent financial results.

What is Bio-Techne’s dividend yield?

Bio-Techne currently has a dividend yield of 0.44%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services